Abstract
Polo-like kinase 1 (Plk1) regulates mitotic progression in all eukaryotes and has been implicated in the transformation of human cells. Analysis of the cytological and anti-tumor activities of BI 2536, a novel, selective pharmacological inhibitor of Plk1, has connected chemistry and biology to the bedside.
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Cell Cycle Proteins / antagonists & inhibitors*
-
Enzyme Inhibitors / pharmacology
-
Humans
-
Mitosis / drug effects*
-
Neoplasms / drug therapy*
-
Polo-Like Kinase 1
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Proto-Oncogene Proteins / antagonists & inhibitors*
-
Pteridines / pharmacology*
-
Pteridines / therapeutic use
Substances
-
Antineoplastic Agents
-
BI 2536
-
Cell Cycle Proteins
-
Enzyme Inhibitors
-
Proto-Oncogene Proteins
-
Pteridines
-
Protein Serine-Threonine Kinases